Wei Lv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wei Lv has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Alan P. Kozikowski
Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States
2 shared publications - Brian Budke
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
2 shared publications - Philip P. Connell
Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medicine & Biological Sciences, Chicago, Illinois
2 shared publications - Michal Pawlowski
Department of Medicinal Chemistry and Pharmacognosy, Drug Discovery Program, University of Illinois at Chicago , Chicago, 833 South Wood Street 539c PHAR, MC 781, Illinois 60612, United States
1 shared publication
Latest Publications
- Open Access
- 1 October 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96 (2) , S16-S17
Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51
- 1 October 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96 (2) , S16-S17
Open AccessDevelopment of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51
- Open Access
- 21 April 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (10) , 4511-4525
Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51
RAD51 is the central protein in homologous recombination (HR) DNA repair and represents a therapeutic target in oncology. Herein we report a novel class of RAD51 inhibitors that were identified by high throughput screening. In contrast to many previously reported RAD51 inhibitors, our lead compound 1 is capable of blocking RAD51-mediated D-loop formation (IC50 21.3 ± 7.8 μM) at concentrations that do not influence RAD51 binding to ssDNA. In human cells, 1 inhibits HR (IC50 13.1 ± 1.6 μM) without blocking RAD51’s ability to assemble into subnuclear foci at sites of DNA damage. We determined that the active constituent of 1 is actually an oxidized derivative (termed RI(dl)-1 or 8) of the original screening compound. Our SAR campaign also yielded RI(dl)-2 (hereafter termed 9h), which effectively blocks RAD51’s D-loop activity in biochemical systems (IC50 11.1 ± 1.3 μM) and inhibits HR activity in human cells (IC50 3.0 ± 1.8 μM).
- 21 April 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (10) , 4511-4525
Open AccessDevelopment of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51
RAD51 is the central protein in homologous recombination (HR) DNA repair and represents a therapeutic target in oncology. Herein we report a novel class of RAD51 inhibitors that were identified by high throughput screening. In contrast to many previously reported RAD51 inhibitors, our lead compound 1 is capable of blocking RAD51-mediated D-loop formation (IC50 21.3 ± 7.8 μM) at concentrations that do not influence RAD51 binding to ssDNA. In human cells, 1 inhibits HR (IC50 13.1 ± 1.6 μM) without blocking RAD51’s ability to assemble into subnuclear foci at sites of DNA damage. We determined that the active constituent of 1 is actually an oxidized derivative (termed RI(dl)-1 or 8) of the original screening compound. Our SAR campaign also yielded RI(dl)-2 (hereafter termed 9h), which effectively blocks RAD51’s D-loop activity in biochemical systems (IC50 11.1 ± 1.3 μM) and inhibits HR activity in human cells (IC50 3.0 ± 1.8 μM).